12/14/2006 | PP | New Issue: Introgen seals $24 million direct placement of shares
|
12/14/2006 | PP | Market Commentary: Linn Energy pockets $360 million from PIPE; Geron gears up to close $40 million stock offering
|
11/7/2006 | PP | Market Commentary: Cytogen to seal $20 million private placement; biotechs lead PIPE activity
|
11/7/2006 | BTPP | New Issue: Introgen completes $6.1 million direct placement of stock
|
11/6/2006 | BT | Introgen ends quarter with $18.9 million, says capital will fund next 9 to 12 months
|
9/7/2006 | BT | Introgen: Advexin gets orphan status in European Union to treat Li-Fraumeni syndrome
|
9/6/2006 | BT | Introgen says Advexin promising as breast-cancer treatment
|
8/9/2006 | BT | Introgen announces key regulatory advance for Advexin program
|
6/6/2006 | BT | Introgen's INGN 241, in combination with Tarceva, shown to inhibit tumor growth
|
6/2/2006 | BT | Introgen says Advexin p53 therapy demonstrates clinical benefit in inherited cancer
|
5/9/2006 | BT | Introgen, Gendux file for European orphan-drug status for Advexin
|
5/8/2006 | BT | Introgen's Advexin p53 used to treat Li-Fraumeni Syndrome cancer patient
|
4/26/2006 | BT | Introgen announces patent for adenoviral p53 manufacturing methods
|
4/4/2006 | BT | Introgen study shows INGN 241 kills chemotherapy-resistant cancer cells
|
4/3/2006 | BT | Introgen demonstrates INGN 241 in combination with Avastin enhances anti-tumor activity
|
3/16/2006 | BT | Introgen trial of Advexin in esophageal cancer demonstrates safety, anti-tumor activity
|
3/15/2006 | BT | Introgen fourth-quarter revenues down by almost half, year-end loss at $26.1 million
|
3/3/2006 | BT | Introgen's Advexin may benefit from FDA approval of new therapy for head, neck cancer
|
2/24/2006 | BT | Introgen reports advances in oncolytic virus program
|
2/23/2006 | BT | Introgen p53 combination cancer therapy patent affirmed
|
2/21/2006 | BT | Introgen reports positive results for phase 2 trial of INGN 225 immunotherapy in lung cancer patients
|
2/14/2006 | BT | Introgen awarded patent for gene-based therapies for cancer
|
12/22/2005 | BT | Introgen requests FDA approval to accelerate interim analysis of Advexin phase 3 trial in head, neck cancer
|
12/20/2005 | BT | Introgen says preclinical data shows injection of oncolytic virus INGN 011 suppresses growth of liver, lung tumors
|
12/12/2005 | BT | Introgen preclinical studies in breast cancer demonstrate INGN 241 reduces tumor growth
|
11/8/2005 | BT | Introgen says study shows INGN 241 with Celebrex may treat breast cancer
|
11/7/2005 | PP | Market Commentary: Homestore wraps $100 million convertible preferreds; Solar settles $37 million note sale
|
11/4/2005 | BTPP | New Issue: Introgen prices $20 million direct placement of stock with Colgate-Palmolive
|
11/4/2005 | BT | Introgen, Colgate-Palmolive to co-develop anti-cancer oral health products
|
11/4/2005 | BT | Market Commentary: Introgen's stock lifts on Colgate-Palmolive alliance; Cytori, Olympus enter into joint venture
|
11/4/2005 | PP | Market Commentary: Introgen arranges $20 million direct stock deal; retreating oil, improved stocks help PIPE volume
|
10/28/2005 | BT | Introgen's INGN 241 therapy found to inhibit tumor growth
|
12/10/2004 | PP | Market Commentary: Private placement volume stalls on lower oil, stocks; Penwest raises $35 million
|
12/10/2004 | PP | New Issue: Introgen Therapeutics sells $7.8 million in shares through direct placement
|
12/8/2004 | PP | New Issue: Introgen raises $16.4 million in direct placement of shares
|
12/8/2004 | PP | Market Commentary: U.S. volume improves slightly on better stocks; Blizzard Energy plans C$50 million deal
|